Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02342730 · ClinicalTrials.gov registry record · NA
Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia
A NA study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 127
- Enrollment target
NCT02342730 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 127 participants.
The verdict
NCT02342730, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 127 participants
- Enrollment target
Study Summary
This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the most common contributors to (causes of) endometrial cancer. Over two-thirds of women who have survived endometrial cancer are obese. Complications of obesity, such as heart disease are often more dangerous than the cancer itself. A weight loss of even 5-10% of excess body weight is associated with improved health. Often, meeting with a doctor or person who is an expert in weight loss (bariatric specialist) is the best way to lose weight and keep it off. Endometrial cancer survivors or patients with atypical hyperplasia who go see a weight loss specialist recommended by their doctor may be able to achieve a healthier body weight.
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Medical Chart Review
- BEHAVIORAL Weight Loss Specialist
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2014-12-17 |
| Est. Completion | 2015-05-18 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02342730
The ClinicalTrials.gov registry entry for NCT02342730 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT02342730 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02342730 about?
NCT02342730 is a clinical study titled "Weight Loss Referral for Healthier Survivorship in Obese Stage I-II Endometrial Cancer Survivors or Atypical Hyperplasia". This pilot clinical trial studies whether obese stage I-II endometrial cancer survivors or patients with atypical hyperplasia (abnormal cells in the lining of the uterus) would go see a weight loss specialist if it was recommended by their cancer doctor. Excess body weight or obesity is one of the m...
What is the current status of trial NCT02342730?
This trial is currently completed. It is a NA study. The enrollment target is 127 participants. The study started on 2014-12-17. Estimated completion is 2015-05-18.
What interventions are being tested in trial NCT02342730?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Medical Chart Review (OTHER), Weight Loss Specialist (BEHAVIORAL).
Who is sponsoring clinical trial NCT02342730?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.